JP5580814B2 - ３環式インドール誘導体およびその使用方法 - Google Patents

３環式インドール誘導体およびその使用方法 Download PDF

Info

Publication number
JP5580814B2
JP5580814B2 JP2011513649A JP2011513649A JP5580814B2 JP 5580814 B2 JP5580814 B2 JP 5580814B2 JP 2011513649 A JP2011513649 A JP 2011513649A JP 2011513649 A JP2011513649 A JP 2011513649A JP 5580814 B2 JP5580814 B2 JP 5580814B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
mmol
acceptable salt
additional antiviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011513649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011524359A5 (https=
JP2011524359A (ja
Inventor
スリカンス ベンカトラマン，
ゴピナダン エヌ． アニルクマール，
ケビン エックス． チェン，
フランシスコ ベラクエス，
チンベイ ツェン，
デュアン リュー，
ユーヘン チャン，
ジョセフ エー． コズロウスキー，
エフ． ジョージ ヌジョロージュ，
ステュアート ビー． ローセンブラム，
スティーブン ジェイ． ガバラス，
パトリック エー． ピント，
オレグ ビー． セルユーティン，
バンチャ ビバルバーン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2011524359A publication Critical patent/JP2011524359A/ja
Publication of JP2011524359A5 publication Critical patent/JP2011524359A5/ja
Application granted granted Critical
Publication of JP5580814B2 publication Critical patent/JP5580814B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2011513649A 2008-06-13 2009-06-10 ３環式インドール誘導体およびその使用方法 Active JP5580814B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6134408P 2008-06-13 2008-06-13
US61/061,344 2008-06-13
PCT/US2009/046822 WO2009152200A1 (en) 2008-06-13 2009-06-10 Tricyclic indole derivatives and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2011524359A JP2011524359A (ja) 2011-09-01
JP2011524359A5 JP2011524359A5 (https=) 2012-06-07
JP5580814B2 true JP5580814B2 (ja) 2014-08-27

Family

ID=40943627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011513649A Active JP5580814B2 (ja) 2008-06-13 2009-06-10 ３環式インドール誘導体およびその使用方法

Country Status (9)

Country Link
US (1) US8901139B2 (https=)
EP (1) EP2303893B1 (https=)
JP (1) JP5580814B2 (https=)
CN (1) CN102159579B (https=)
AR (1) AR072088A1 (https=)
CA (1) CA2727620A1 (https=)
MX (1) MX2010013630A (https=)
TW (1) TW201011030A (https=)
WO (1) WO2009152200A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007339382B2 (en) 2006-12-22 2013-05-02 Merck Sharp & Dohme Llc 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
KR102127406B1 (ko) 2012-09-20 2020-06-29 유디씨 아일랜드 리미티드 전자 응용을 위한 아자디벤조푸란
ES2688147T3 (es) 2014-03-21 2018-10-31 Bristol-Myers Squibb Company Compuestos de 6H-furo[2,3-e]indol para el tratamiento de la hepatitis C
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
WO2018151239A1 (ja) * 2017-02-17 2018-08-23 第一三共株式会社 ３，６－ジヒドロ－２Ｈ－フロ［２，３－ｅ］インドール化合物
CN116063310A (zh) * 2022-12-23 2023-05-05 齐鲁工业大学 一种呋喃并[3,4-b]吲哚衍生物及其合成方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE648639C (de) 1935-05-19 1937-08-05 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Dipyrrolen
US3632805A (en) * 1967-12-08 1972-01-04 Sumitomo Chemical Co Process for producing 1-aminoalkyl-benzodiazepine derivatives
AU575854B2 (en) * 1983-10-04 1988-08-11 Shionogi & Co., Ltd. 7beta-(carboxyalkenamido) cephalosporins
NZ220764A (en) * 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
US5017380A (en) * 1986-07-02 1991-05-21 Shionogi & Co., Ltd. Gelatin hard capsule containing crystalline hydrate of oral cephalosporin
CA2038925A1 (en) 1990-03-26 1991-09-27 Takashi Sohda Indole derivatives, their production and use
JPH04149429A (ja) 1990-10-12 1992-05-22 Fuji Photo Film Co Ltd ハロゲン化銀カラー反転写真感光材料およびそれを用いた画像形成方法
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
AP1019A (en) 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
FR2768146B1 (fr) 1997-09-05 2000-05-05 Oreal Nouveaux composes de la famille des indole-carboxyliques et leur utilisation
ES2317900T3 (es) * 2000-04-05 2009-05-01 Schering Corporation Inhibidores de serina proteasa ns3 macrociclicos del virus de la hepatitis c que comprenden fragmentos n-ciclicas p2.
AU2001253621A1 (en) * 2000-04-19 2001-11-07 Schering Corporation Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
AR034127A1 (es) * 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
CN1498224A (zh) * 2000-07-21 2004-05-19 ���鹫˾ 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
SK742003A3 (en) * 2000-07-21 2003-06-03 Schering Corp Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
PL366068A1 (en) 2000-10-10 2005-01-24 Smithkline Beecham Corporation Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents
AU3659102A (en) * 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
WO2002050030A2 (en) * 2000-12-18 2002-06-27 Eli Lilly And Company Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
US7626026B2 (en) 2001-02-22 2009-12-01 University Of Bradford Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
WO2004035571A1 (en) 2002-10-15 2004-04-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
US20050075331A1 (en) * 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
CN1832939B (zh) 2003-05-30 2010-04-28 杰明X医药品加拿大公司 用于治疗癌症或病毒病的三杂环化合物、组合物和方法
GB0323845D0 (en) 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
PE20050925A1 (es) * 2003-11-10 2005-11-29 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
EP1714427A1 (de) 2004-02-09 2006-10-25 Hörmann KG Antriebstechnik Torantriebssystem mit seriellem bus für kommunikation der komponenten
CN103102389A (zh) 2004-02-27 2013-05-15 默沙东公司 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物
JP2007526320A (ja) * 2004-03-01 2007-09-13 バイロファーマ・インコーポレイテッド ピラノインドール誘導体およびｃ型肝炎ウイルス感染症または疾患の治療のためのその使用
US20050249702A1 (en) * 2004-05-06 2005-11-10 Schering Corporation (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
MX2007003371A (es) 2004-09-23 2007-05-07 Wyeth Corp Derivados de carbazol y ciclopentaindol para tratar infeccion con virus de hepatitis c.
DE102004047272A1 (de) 2004-09-24 2006-04-06 Schering Ag Inhibitoren der löslichen Adenylatzyklase
EP1807403A2 (en) 2004-10-26 2007-07-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Tetracyclic indole derivatives as antiviral agents
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7482360B2 (en) 2005-09-23 2009-01-27 Schering Corporation Fused tetracyclic mGluR1 antagonists as therapeutic agents
JP2009523732A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
EP1981524A2 (en) * 2006-02-09 2008-10-22 Schering Corporation Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto
AU2007339382B2 (en) * 2006-12-22 2013-05-02 Merck Sharp & Dohme Llc 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
EP2081922B1 (en) * 2006-12-22 2012-02-01 Schering Corporation 5,6-Ring annulated indole derivatives and use thereof
JP5211068B2 (ja) * 2006-12-22 2013-06-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体
EP2197884A2 (en) * 2007-08-29 2010-06-23 Schering Corporation Tetracyclic indole derivatives and their use for treating or preventing viral infections
WO2009032116A1 (en) * 2007-08-29 2009-03-12 Schering Corporation 2, 3-substituted indole derivatives for treating viral infections
ATE541845T1 (de) * 2007-08-29 2012-02-15 Schering Corp 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen
TW200924780A (en) * 2007-08-29 2009-06-16 Schering Corp 2-carboxy substituted indole derivatives and methods of use thereof
CA2705587A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
MX2010005356A (es) * 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.

Also Published As

Publication number Publication date
JP2011524359A (ja) 2011-09-01
EP2303893A1 (en) 2011-04-06
AR072088A1 (es) 2010-08-04
CA2727620A1 (en) 2009-12-17
CN102159579B (zh) 2015-03-25
TW201011030A (en) 2010-03-16
US8901139B2 (en) 2014-12-02
US20110189127A1 (en) 2011-08-04
WO2009152200A1 (en) 2009-12-17
MX2010013630A (es) 2010-12-21
EP2303893B1 (en) 2016-12-07
CN102159579A (zh) 2011-08-17

Similar Documents

Publication Publication Date Title
JP5055377B2 (ja) ［５，６−環］環形成インドール誘導体およびその使用方法
JP5258889B2 (ja) ウイルス感染症の治療のための２，３−置換アザインドール誘導体
JP5272008B2 (ja) 置換インドール誘導体およびその使用の方法
JP5179585B2 (ja) 四環系インドール誘導体およびその使用法
EP2064180B1 (en) 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
JP5211068B2 (ja) Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体
JP5272007B2 (ja) ウイルス感染症を治療するための２，３−置換インドール誘導体
JP5580814B2 (ja) ３環式インドール誘導体およびその使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140116

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140617

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140711

R150 Certificate of patent or registration of utility model

Ref document number: 5580814

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250